Zoetis says Neogen deal won't lessen competition after ACCC Phase 2 decision
Zoetis’ proposed acquisition of Neogen’s Genomics Business would not raise competition concerns in Australia, the company said after the country’s antitrust regulator announced the deal would require an in-depth Phase 2...To view the full article, register now.
Already a subscriber? Click here to view full article